Precipio Inc (PRPO) — Titan Protect Analysis

PRPO

Precipio Inc

Healthcare · ·

$23.49

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$40M

Total market value of the company

Trailing P/E

N/A

Forward P/E

57.87

Based on estimated future earnings — lower means cheaper

Rev Growth

+22.9%

Year-over-year revenue change

Profit Margin

-1.5%

How much profit the company keeps from each dollar of revenue

ROE

-2.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Precipio Inc

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Hav

https://www.precipiodx.com

Country: United States Employees: 61 Industry: Diagnostics & Research

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

1.264

Excellent risk-adjusted returns

Kelly Fraction

0.0857

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.864

Returns exceed worst-case losses — strong risk profile

Annual Return

103.7%

Historical annualised return based on price data

Max Drawdown

-55.6%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

134

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.38

Moves slightly more than the broader market

52W High

$33.63

30% below the year high

52W Low

$9.67

143% above the year low

Avg Volume

32,468

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.45

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

25.09

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

44.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

8.1%

Profit from core operations before interest and tax

Free Cash Flow

$210,125

Positive — the business generates more cash than it spends

Revenue (TTM)

$24M

Total revenue over the last 12 months

Net Income

$-363,000

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go